A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

Sponsor
UCB Celltech
Study ID
NCT05028127
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Bimekizumab — DRUG
    Subjects will be receiving bimekizumab at pre-specified time-points.

Study Details

The purpose of the study to determine the relative bioavailability of bimekizumab in healthy subjects

Key Dates

Start date
Mar 4, 2016
Status verified
Aug 2021
Primary completion
Jun 17, 2016
Completion
Jun 17, 2016

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Bimekizumab dosage regimen 1
    Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.
  • Experimental: Bimekizumab dosage regimen 2
    Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.

Primary Outcome Measure

Number of Adverse Events including injection site reactions and systemic injection reactions [ Time Frame: From Screening Period (Day -21) until end of Safety-Follow-Up Visit (up to Day 85) ]

Related Studies